$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023005259 Filed on February 27, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$68.78M	$79.55M	$270.8M
YoY Change	37.77%	68.68%	72.31%
Cost Of Revenue	$938.0K	$2.496M	$6.408M
YoY Change	297.46%	495.7%	-11.36%
Gross Profit	$67.84M	$77.05M	$264.4M
YoY Change	36.53%	64.85%	76.35%
Gross Profit Margin	98.64%	96.86%	97.63%
Selling, General & Admin	$47.87M	$50.15M	$159.4M
YoY Change	39.63%	41.73%	34.13%
% of Gross Profit	70.56%	65.09%	60.27%
Research & Development	$48.39M	$73.21M	$253.3M
YoY Change	-25.97%	15.23%	21.31%
% of Gross Profit	71.33%	95.01%	95.79%
Depreciation & Amortization	$405.0K	$396.0K	$1.437M
YoY Change	27.76%	131.58%	84.94%
% of Gross Profit	0.6%	0.51%	0.54%
Operating Expenses	$96.26M	$123.4M	$412.7M
YoY Change	-3.4%	24.71%	25.96%
Operating Profit	-$28.42M	-$46.31M	-$148.4M
YoY Change	-43.12%	-11.24%	-16.48%
Interest Expense	-$24.25M	-$25.15M	$99.09M
YoY Change	-201.72%	31.1%	67.12%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$52.66M	-$71.47M	-$244.4M
YoY Change	-28.76%	360.29%	34.42%
Income Tax	$671.0K	$76.00K	$2.733M
% Of Pretax Income
Net Earnings	-$53.33M	-$71.54M	-$247.1M
YoY Change	-28.12%	302.39%	34.26%
Net Earnings / Revenue	-77.54%	-89.94%	-91.24%
Basic Earnings Per Share	-$0.28		-$1.33
Diluted Earnings Per Share	-$0.28	-$0.38	-$1.33
COMMON SHARES
Basic Shares Outstanding	188.5M shares	186.4M shares	185.9M shares
Diluted Shares Outstanding	188.5M shares		185.9M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$398.2M	$424.3M	$424.3M
YoY Change	-10.22%	-16.41%	-16.41%
Cash & Equivalents	$155.1M	$304.8M	$304.8M
Short-Term Investments	$243.0M	$119.5M	$119.5M
Other Short-Term Assets	$16.62M	$14.06M	$14.06M
YoY Change	5.95%	5.45%	5.45%
Inventory	$27.47M	$27.53M	$27.53M
Prepaid Expenses
Receivables	$48.64M	$50.60M	$50.60M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$490.9M	$516.5M	$516.5M
YoY Change	-4.07%	-8.77%	-8.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.376M	$8.617M	$15.42M
YoY Change	-4.81%	-1.11%	1.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.432M	$18.08M	$18.08M
YoY Change		164.71%	164.71%
Other Assets	$7.046M	$6.806M
YoY Change	-2.23%	5.16%
Total Long-Term Assets	$18.85M	$33.50M	$33.50M
YoY Change	17.79%	52.17%	52.17%
TOTAL ASSETS
Total Short-Term Assets	$490.9M	$516.5M	$516.5M
Total Long-Term Assets	$18.85M	$33.50M	$33.50M
Total Assets	$509.7M	$550.0M	$550.0M
YoY Change	-3.41%	-6.49%	-6.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.254M	$14.36M	$14.36M
YoY Change	-54.95%	-48.37%	-48.37%
Accrued Expenses	$75.21M	$87.57M	$89.93M
YoY Change	18.29%	20.5%	20.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$85.16M	$105.5M	$105.5M
YoY Change	5.11%	1.73%	1.73%
LONG-TERM LIABILITIES
Long-Term Debt	$232.5M	$231.6M	$733.3M
YoY Change	65.81%	70.21%	25.25%
Other Long-Term Liabilities	$5.934M	$5.804M	$5.804M
YoY Change	-8.1%	-2.65%	-2.65%
Total Long-Term Liabilities	$232.5M	$231.6M	$739.1M
YoY Change	65.81%	70.21%	24.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$85.16M	$105.5M	$105.5M
Total Long-Term Liabilities	$232.5M	$231.6M	$739.1M
Total Liabilities	$317.7M	$337.1M	$844.6M
YoY Change	43.58%	40.59%	21.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.508B	-$1.455B
YoY Change	17.65%	20.47%
Common Stock	$1.889M	$1.879M
YoY Change	1.78%	1.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$328.3M	-$294.6M	-$294.6M
YoY Change
Total Liabilities & Shareholders Equity	$509.7M	$550.0M	$550.0M
YoY Change	-3.41%	-6.49%	-6.49%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$53.33M	-$71.54M	-$247.1M
YoY Change	-28.12%	302.39%	34.26%
Depreciation, Depletion And Amortization	$405.0K	$396.0K	$1.437M
YoY Change	27.76%	131.58%	84.94%
Cash From Operating Activities	-$47.51M	-$23.85M	-$161.9M
YoY Change	-38.93%	-26.53%	13.85%
INVESTING ACTIVITIES
Capital Expenditures	$160.0K	$526.0K	$1.351M
YoY Change	-139.41%	-147.47%	-156.65%
Acquisitions
YoY Change
Other Investing Activities	-$106.9M	$77.74M	-$126.9M
YoY Change	180.96%	-876.48%	-797.6%
Cash From Investing Activities	-$107.1M	$77.22M	-$128.2M
YoY Change	178.41%	-794.38%	-911.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.077M	4.199M	$88.03M
YoY Change	-30.98%	-98.79%	-75.53%
NET CHANGE
Cash From Operating Activities	-$47.51M	-23.85M	-$161.9M
Cash From Investing Activities	-$107.1M	77.22M	-$128.2M
Cash From Financing Activities	$5.077M	4.199M	$88.03M
Net Change In Cash	-$149.6M	57.57M	-$201.5M
YoY Change	37.44%	-81.05%	-186.34%
FREE CASH FLOW
Cash From Operating Activities	-$47.51M	-$23.85M	-$161.9M
Capital Expenditures	$160.0K	$526.0K	$1.351M
Free Cash Flow	-$47.67M	-$24.37M	-$163.2M
YoY Change	-38.4%	-22.25%	16.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000882796
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AvailableForSaleSecuritiesDebtSecuritiesCurrent http://fasb.org/us-gaap/2022#LongTermInvestments
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022	us-gaap	Open Tax Year OpenTaxYear	2018 2019 2020 2021
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-23186
CY2022	dei	Entity Registrant Name EntityRegistrantName	BIOCRYST PHARMACEUTICALS, INC.
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	62-1413174
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	4505 Emperor Blvd., Suite 200
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Durham
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27703
CY2022	dei	City Area Code CityAreaCode	919
CY2022	dei	Local Phone Number LocalPhoneNumber	859-1302
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2022	dei	Trading Symbol TradingSymbol	BCRX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	1949284603	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	188451137	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304767000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	504389000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1472000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	3345000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	119543000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	3212000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	50599000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29413000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	27533000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	15791000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12586000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9986000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	516500000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	566136000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8617000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8714000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	18077000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	6829000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6806000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6472000	usd
CY2022Q4	us-gaap	Assets Assets	550000000	usd
CY2021Q4	us-gaap	Assets Assets	588151000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14356000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27808000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87565000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	72670000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1224000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1421000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2369000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1819000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	105514000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	103718000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5804000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5962000	usd
CY2022Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	501655000	usd
CY2021Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	449375000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	231624000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	136082000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	187906000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187906000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184350000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184350000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1879000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1843000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1158118000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1098498000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	177000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1454620000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1207504000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-294597000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-106986000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	550000000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	588151000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	270827000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	157170000	usd
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17812000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6408000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7229000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1550000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	253297000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	208808000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	122964000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	159371000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	118818000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	67929000	usd
CY2022	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	186000	usd
CY2021	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	35000	usd
CY2020	bcrx	Royalty Expense Reversal Of Expense RoyaltyExpenseReversalOfExpense	126000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	419262000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	334890000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	192569000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-148435000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-177720000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-174757000	usd
CY2022	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	5127000	usd
CY2021	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	62000	usd
CY2020	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	9420000	usd
CY2022	us-gaap	Interest Expense InterestExpense	99092000	usd
CY2021	us-gaap	Interest Expense InterestExpense	59294000	usd
CY2020	us-gaap	Interest Expense InterestExpense	14501000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	55838000	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2011000	usd
CY2022	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-1983000	usd
CY2021	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-695000	usd
CY2020	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-965000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-244383000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181809000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-182814000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2733000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2253000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-247116000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-184062000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-182814000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	890000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	189000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1041000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-15000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-36000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-247267000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-183888000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-182850000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.33
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	185908000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	185908000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179117000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179117000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	167267000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	167267000	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-247116000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-184062000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-182814000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1437000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	777000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	748000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	932000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	44701000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	34640000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	14794000	usd
CY2022	bcrx	Noncash Interest Expense And Amortization Of Debt Issuance Costs NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts	98918000	usd
CY2021	bcrx	Noncash Interest Expense And Amortization Of Debt Issuance Costs NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts	54204000	usd
CY2020	bcrx	Noncash Interest Expense And Amortization Of Debt Issuance Costs NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts	3325000	usd
CY2022	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-1777000	usd
CY2021	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-2000	usd
CY2020	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	121000	usd
CY2022	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	0	usd
CY2021	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	0	usd
CY2020	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-632000	usd
CY2022	bcrx	Increase Decrease In Extinguishment Of Debt IncreaseDecreaseInExtinguishmentOfDebt	0	usd
CY2021	bcrx	Increase Decrease In Extinguishment Of Debt IncreaseDecreaseInExtinguishmentOfDebt	55838000	usd
CY2020	bcrx	Increase Decrease In Extinguishment Of Debt IncreaseDecreaseInExtinguishmentOfDebt	-1211000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	21470000	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	20817000	usd
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-13903000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12423000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8767000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7039000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2583000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7155000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2140000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22360000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	39412000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	17355000	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	4168000	usd
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	6766000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-109000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1283000	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1970000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-161850000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-142157000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-135108000	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1351000	usd
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2385000	usd
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	514000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	244283000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10012000	usd
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	49818000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	117396000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	28201000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	43476000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-128238000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15804000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6856000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	93279000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	14817000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14955000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15794000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2446000	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	73072000	usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	52420000	usd
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	119867000	usd
CY2022	bcrx	Proceeds From Royalty Financing Obligation ProceedsFromRoyaltyFinancingObligation	0	usd
CY2021	bcrx	Proceeds From Royalty Financing Obligation ProceedsFromRoyaltyFinancingObligation	293874000	usd
CY2020	bcrx	Proceeds From Royalty Financing Obligation ProceedsFromRoyaltyFinancingObligation	122600000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	88027000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	359668000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	300589000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	566000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-201495000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	233386000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	158625000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	507734000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	274348000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	115723000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	306239000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	507734000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	274348000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	38252000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-182814000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-36000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1814000	usd
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	632000	usd
CY2020	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	22044000	shares
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	93279000	usd
CY2020	bcrx	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	3511000	shares
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	14817000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14794000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-19262000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-184062000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	174000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13805000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1989000	usd
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3846000	shares
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45730000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34640000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-106986000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-247116000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-151000	usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3044000	shares
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12090000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2862000	usd
CY2022	bcrx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	253000	shares
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44701000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-294597000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to </span></div>the valuation of stock options, the ORLADEYO and Factor D inhibitors royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
CY2022	bcrx	Longterm Investment Maturity Minimum LongtermInvestmentMaturityMinimum	P12Y
CY2022Q4	us-gaap	Inventory Adjustments InventoryAdjustments	932000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1177000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	14891000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	5705000	usd
CY2020	us-gaap	Advertising Expense AdvertisingExpense	6567000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	99092000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	59294000	usd
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	14501000	usd
CY2022	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	-916000	usd
CY2021	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	-531000	usd
CY2020	bcrx	Amortization Of Debt Financing Costs And Original Issue Discounts AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts	1217000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	270827000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25596	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26034	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14957	shares
CY2021	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	1000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	157170000	usd
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17812000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	138196000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	487000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1063000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137620000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	9989000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	65000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10041000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	119543000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3212000	usd
CY2022Q4	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	18077000	usd
CY2021Q4	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	6829000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137620000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	10041000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	8268000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1980000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8906000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5658000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14990000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9669000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4814000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	709000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	28710000	usd
CY2021Q4	us-gaap	Inventory Gross InventoryGross	16036000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1177000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	245000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	27533000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	15791000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18167000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16827000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9550000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8113000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8617000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8714000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1437000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	777000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	748000	usd
CY2022Q4	bcrx	Accrued Development Costs AccruedDevelopmentCosts	30360000	usd
CY2021Q4	bcrx	Accrued Development Costs AccruedDevelopmentCosts	30215000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22125000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20674000	usd
CY2022Q4	bcrx	Revenue Related Reserves For Discounts And Allowances RevenueRelatedReservesForDiscountsAndAllowances	14332000	usd
CY2021Q4	bcrx	Revenue Related Reserves For Discounts And Allowances RevenueRelatedReservesForDiscountsAndAllowances	5957000	usd
CY2022Q4	bcrx	Royalties Payable RoyaltiesPayable	7700000	usd
CY2021Q4	bcrx	Royalties Payable RoyaltiesPayable	4426000	usd
CY2022Q4	bcrx	Accrued Inventory Expense AccruedInventoryExpense	4193000	usd
CY2021Q4	bcrx	Accrued Inventory Expense AccruedInventoryExpense	3793000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1128000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1305000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	410000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2622000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7317000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3678000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87565000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	72670000	usd
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	122609000	usd
CY2020	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	2108000	usd
CY2020Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	124717000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	298142000	usd
CY2021	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	37670000	usd
CY2021	bcrx	Royalties Revenues Paid And Payable RoyaltiesRevenuesPaidAndPayable	-11154000	usd
CY2021Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	449375000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	34000	usd
CY2022	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	76482000	usd
CY2022	bcrx	Royalties Revenues Paid And Payable RoyaltiesRevenuesPaidAndPayable	-24168000	usd
CY2022Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	501655000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	2532000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1795000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1096
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1120
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6806000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6472000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2369000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1819000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5804000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5962000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8173000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7781000	usd
CY2022Q4	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	4349000	usd
CY2021Q4	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	2626000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2453000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1615000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2621000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1958000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1541000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	656000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	613000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6112000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13501000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5328000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8173000	usd
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	22044000	shares
CY2020Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.50
CY2020Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	108096000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44701000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34640000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14794000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	148700000	usd
CY2022Q4	bcrx	Employee Service Shar Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Next Year EmployeeServiceSharBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear	50713000	usd
CY2022Q4	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	46329000	usd
CY2022Q4	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	34537000	usd
CY2022Q4	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	17121000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44701000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34640000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14794000	usd
CY2022	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0
CY2022	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	18
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	36520	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	8.59
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	18828	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	7.17
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	17532000	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.06
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7603000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.03
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	5908000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	5.68
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1535000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	6.24
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	17692000	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.02
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	260000	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	321000	shares
CY2020	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	246000	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-225127000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-159632000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-19256000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-51321000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-22177000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-244383000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181809000	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	2430000	usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	2179000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	292000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	233000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2722000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2412000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	11000	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-159000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2733000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2253000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-38175000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-38391000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1816000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2288000	usd
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2544000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1608000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1343000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	774000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-82000	usd
CY2022	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	0	usd
CY2021	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	-1057000	usd
CY2020	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	3774000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	9793000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5994000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4080000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1862000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1940000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	542000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-5485000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1216000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1456000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	70894000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	47954000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	38551000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2733000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2253000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9729000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8230000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4115000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1499000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13844000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9729000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	101600000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	113649000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	86321000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	71197000	usd
CY2022Q4	bcrx	Deferred Tax Assets Royalty Income DeferredTaxAssetsRoyaltyIncome	115554000	usd
CY2021Q4	bcrx	Deferred Tax Assets Royalty Income DeferredTaxAssetsRoyaltyIncome	106007000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	19374000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14512000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	62794000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	8997000	usd
CY2022Q4	bcrx	Deferred Tax Assets Leasing Obligations DeferredTaxAssetsLeasingObligations	1842000	usd
CY2021Q4	bcrx	Deferred Tax Assets Leasing Obligations DeferredTaxAssetsLeasingObligations	1836000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4354000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4809000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	391839000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	321007000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	717000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	607000	usd
CY2022Q4	bcrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	1525000	usd
CY2021Q4	bcrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	1527000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2242000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2134000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	389608000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	318714000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	159000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	70894000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	47954000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	38551000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3758000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2834000	usd
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1569000	usd
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Raleigh, North Carolina
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Raleigh, North Carolina
CY2022	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
bcrx-20221231_cal.xml	Edgar Link	unprocessable
0001628280-23-005259-index-headers.html	Edgar Link	pending
0001628280-23-005259-index.html	Edgar Link	pending
0001628280-23-005259.txt	Edgar Link	pending
0001628280-23-005259-xbrl.zip	Edgar Link	pending
bcrx-20221231.htm	Edgar Link	pending
bcrx-20221231.xsd	Edgar Link	pending
bcrx-20221231xex311.htm	Edgar Link	pending
bcrx-20221231xex312.htm	Edgar Link	pending
bcrx-20221231xex321.htm	Edgar Link	pending
bcrx-20221231xex322.htm	Edgar Link	pending
bcrx-20221231_g1.jpg	Edgar Link	pending
exhibit21-subsidiaries.htm	Edgar Link	pending
exhibit23-fy22form10xkcons.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
formofnoticeofgrantofrsuan.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
bcrx-20221231_def.xml	Edgar Link	unprocessable
bcrx-20221231_pre.xml	Edgar Link	unprocessable
bcrx-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bcrx-20221231_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2023 Q1 Form 10-K Financial Statement

#000162828023005259 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2023 Q1 Form 10-K Financial Statement

#000162828023005259 Filed on February 27, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx